Amneal Pharmaceuticals, Inc. (AMRX) Key Metrics
AMRX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $6.68B
- Enterprise value
- $9.40B
- P/E (TTM)
- 39.1 10-yr median 12.1
- Forward P/E
- 6.3
- PEG ratio
- —
- Price / sales
- 2.1 10-yr median 0.7
- Price / book
- 204.0 10-yr median 2.1
- EV / EBITDA
- 15.1 10-yr median 10.8
- Dividend yield
- —
- Beta
- 1.22
AMRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAMRX valuation Price multiples at each fiscal year-end price.
AMRX returns How much profit the business earns on the capital it uses.
AMRX per-share figures Results divided by the shares outstanding at year-end.
AMRX financial health Debt, liquidity and how easily interest is covered.
AMRX efficiency & capital use Working capital cycle and where the cash goes.
AMRX valuation history
AMRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AMRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AMRX cash returned to shareholders
AMRX price vs earnings per share
AMRX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.09B | $2.45B | $1.07B | $300.4M | $727.2M | $680.5M | $636.8M | $1.72B | $1.91B | $2.50B |
| Enterprise value | $6.52B | $4.93B | $3.73B | $3.12B | $3.36B | $3.34B | $3.25B | $4.20B | $3.32B | $3.67B |
| P/E ratio | 56.8 | — | — | — | 68.5 | 7.5 | — | — | 11.4 | 12.1 |
| Price / sales | 1.4 | 0.9 | 0.4 | 0.1 | 0.3 | 0.3 | 0.4 | 1.0 | 1.9 | 2.5 |
| Price / book | — | — | 54.0 | 1.0 | 2.0 | 2.2 | 2.7 | 1.9 | — | — |
| Price / free cash flow | 15.2 | 11.1 | 3.9 | — | 3.7 | 2.1 | — | 11.2 | 15.9 | — |
| Price / operating cash flow | 12.0 | 8.3 | 3.1 | 4.6 | 3.0 | 1.8 | 373.5 | 6.9 | 8.2 | 21.8 |
| EV / sales | 2.2 | 1.8 | 1.6 | 1.4 | 1.6 | 1.7 | 2.0 | 2.5 | 3.2 | 3.6 |
| EV / EBITDA | 10.8 | 11.2 | 7.4 | 7.1 | 8.4 | 9.7 | 21.0 | — | 12.3 | 12.0 |
| EV / free cash flow | 24.1 | 22.4 | 13.5 | — | 17.3 | 10.5 | — | 27.4 | 27.7 | — |
| Earnings yield | 1.8% | −4.8% | −7.9% | −43.3% | 1.5% | 13.4% | −56.8% | −9.9% | 8.8% | 8.3% |
| Free cash flow yield | 6.6% | 9.0% | 25.9% | −8.5% | 26.7% | 46.6% | −15.0% | 8.9% | 6.3% | −0.4% |
| Dividend yield | — | — | — | 1.2% | — | — | 0.0% | 10.6% | 19.6% | 8.0% |
| Shareholder yield (dividends + buybacks) | — | 0.3% | 0.2% | 2.4% | 0.4% | 0.1% | 0.1% | 11.1% | 19.6% | 8.0% |
| Share price at fiscal year-end | $12.60 | $7.92 | $6.07 | $1.99 | $4.79 | $4.57 | $4.82 | $13.53 | $16.65 | $13.25 |
| Per share | ||||||||||
| Revenue per share | $9.29 | $9.04 | $13.59 | $14.66 | $13.79 | $13.38 | $12.31 | $13.07 | $9.00 | $5.39 |
| Earnings per share | $0.22 | −$0.38 | −$0.48 | −$0.86 | $0.07 | $0.61 | −$2.74 | −$1.33 | $1.46 | $1.10 |
| Operating cash flow per share | $1.05 | $0.96 | $1.96 | $0.43 | $1.59 | $2.55 | $0.01 | $1.97 | $2.04 | $0.61 |
| Free cash flow per share | $0.83 | $0.71 | $1.57 | −$0.17 | $1.28 | $2.13 | −$0.72 | $1.20 | $1.04 | −$0.05 |
| Cash per share | $0.96 | $0.36 | $0.53 | $0.18 | $1.63 | $2.30 | $1.15 | $1.68 | $0.65 | $0.17 |
| Book value per share | −$0.22 | −$0.35 | $0.11 | $1.98 | $2.37 | $2.04 | $1.76 | $7.04 | −$3.36 | −$0.98 |
| Tangible book value per share | −$3.79 | −$4.66 | −$8.34 | −$9.25 | −$9.22 | −$10.24 | −$11.89 | −$9.31 | −$3.98 | −$1.37 |
| Dividends per share | — | — | — | $0.02 | — | — | $0.00 | $1.44 | $3.27 | $1.06 |
| Capex per share | $0.22 | $0.24 | $0.39 | $0.60 | $0.31 | $0.42 | $0.74 | $0.76 | $0.99 | $0.66 |
| Debt per share | $8.42 | $8.39 | $15.62 | $18.85 | $18.94 | $20.14 | $20.97 | $21.15 | $12.93 | $6.34 |
| Shares outstanding | 324.8M | 309.0M | 176.1M | 150.9M | 151.8M | 148.9M | 132.1M | 127.3M | 114.9M | 189.0M |
| Change in shares outstanding | +5.1% | +75.4% | +16.7% | −0.6% | +2.0% | +12.7% | +3.8% | +10.8% | −39.2% | 0.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | −52.8% | −39.5% | 3.2% | 34.0% | −64.1% | −66.5% | — | — |
| Return on invested capital (ROIC) | 16.5% | 7.8% | 5.6% | −2.5% | 3.3% | 2.5% | −6.3% | −0.7% | 24.2% | 32.1% |
| Return on assets (ROA) | 2.0% | −3.4% | −2.3% | −3.4% | 0.3% | 2.4% | −9.0% | −6.0% | 13.1% | 18.6% |
| Return on tangible assets | 2.9% | −5.4% | −4.2% | −6.2% | 0.5% | 4.2% | −19.4% | −7.5% | 13.2% | 18.1% |
| Free cash flow margin | 8.9% | 7.9% | 11.5% | −1.2% | 9.3% | 15.9% | −5.9% | 9.2% | 11.6% | −0.9% |
| Income quality (OCF / net income) | 4.72 | — | — | — | 22.76 | 4.16 | — | — | 1.40 | 0.55 |
| Financial health | ||||||||||
| Total debt | $2.74B | $2.59B | $2.75B | $2.85B | $2.88B | $3.00B | $2.77B | $2.69B | $1.48B | $1.20B |
| Cash & short-term investments | $310.9M | $112.4M | $93.7M | $27.8M | $247.8M | $343.1M | $152.3M | $213.4M | $74.2M | $31.7M |
| Net debt | $2.43B | $2.48B | $2.66B | $2.82B | $2.63B | $2.66B | $2.62B | $2.48B | $1.41B | $1.17B |
| Debt / equity | — | — | 139.05 | 9.53 | 7.98 | 9.89 | 11.94 | 3.00 | — | — |
| Debt / assets | 0.74 | 0.74 | 0.79 | 0.75 | 0.73 | 0.75 | 0.76 | 0.62 | 1.11 | 0.98 |
| Net debt / EBITDA | 4.02 | 5.64 | 5.31 | 6.40 | 6.55 | 7.68 | 16.87 | — | 5.20 | 3.80 |
| Current ratio | 2.17 | 1.41 | 1.63 | 1.88 | 2.24 | 2.29 | 2.20 | 2.32 | 2.60 | 3.23 |
| Quick ratio | 1.48 | 0.86 | 0.94 | 1.17 | 1.52 | 1.57 | 1.51 | 1.50 | 1.64 | 2.04 |
| Interest coverage | 1.8 | 1.0 | 1.0 | -0.6 | 1.1 | 0.6 | -1.5 | -0.1 | 3.4 | 5.2 |
| Working capital | $1.03B | $458.0M | $531.3M | $659.0M | $842.9M | $874.6M | $659.8M | $732.8M | $475.1M | $501.0M |
| Invested capital | $2.35B | $2.37B | $2.68B | $3.12B | $2.99B | $2.96B | $2.85B | $3.37B | $1.02B | $980.5M |
| Tangible asset value | −$1.15B | −$1.37B | −$1.43B | −$1.49B | −$1.39B | −$1.47B | −$1.46B | −$1.18B | −$446.6M | −$250.3M |
| Net current asset value | −$1.76B | −$1.96B | −$2.03B | −$2.18B | −$2.05B | −$2.10B | −$2.11B | −$2.17B | −$945.5M | −$668.6M |
| Graham number | — | — | — | — | $1.93 | $5.29 | — | — | — | — |
| Graham net-net per share | −$7.25 | −$8.24 | −$14.44 | −$18.16 | −$16.86 | −$17.34 | −$19.10 | −$20.36 | −$10.78 | −$4.94 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $3.6M | — | — | $0 | $183.0M | $375.3M | $200.6M |
| Share buybacks (net) | — | $8.0M | $2.4M | $3.6M | $2.7M | $863,000 | $926,000 | $7.6M | $0 | $0 |
| Dividend payout ratio | — | — | — | — | — | — | — | — | 223.8% | 96.7% |
| Dividends + buybacks / free cash flow | — | 3.6% | 0.9% | — | 1.4% | 0.3% | — | 124.5% | 312.9% | — |
| Capex / revenue | 2.3% | 2.7% | 2.9% | 4.1% | 2.3% | 3.1% | 6.0% | 5.8% | 11.1% | 12.2% |
| Capex / operating cash flow | 20.6% | 25.4% | 20.0% | 139.2% | 19.7% | 16.3% | 5,714.4% | 38.8% | 48.8% | 108.3% |
| Capex / depreciation | 0.31 | 0.32 | 0.30 | 0.38 | 0.20 | 0.26 | 0.47 | 0.71 | 2.49 | 3.77 |
| Stock-based compensation / revenue | 1.1% | 1.0% | 1.1% | 1.4% | 1.4% | 1.0% | 1.3% | 10.1% | 0.5% | 2.1% |
| R&D / revenue | 6.2% | 6.8% | 8.1% | 9.4% | 10.0% | 9.6% | 12.4% | 12.7% | 18.6% | 20.1% |
| SG&A / revenue | 17.5% | 17.1% | 18.0% | 18.1% | 17.5% | 16.4% | 17.8% | 13.9% | 10.5% | 11.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 103.7 | 92.8 | 105.8 | 118.5 | 116.3 | 113.9 | 131.3 | 100.6 | 131.7 | 119.8 |
| Days of inventory on hand | 118.1 | 122.8 | 132.7 | 131.0 | 135.0 | 116.6 | 120.1 | 142.9 | 197.9 | 217.4 |
| Days payables outstanding | 49.9 | 41.5 | 37.0 | 38.3 | 39.3 | 34.4 | 31.2 | 35.6 | 46.8 | 56.4 |
| Cash conversion cycle (days) | 172.0 | 174.2 | 201.4 | 211.3 | 212.0 | 196.1 | 220.2 | 207.9 | 282.8 | 280.8 |
| Receivables turnover | 3.52 | 3.93 | 3.45 | 3.08 | 3.14 | 3.20 | 2.78 | 3.63 | 2.77 | 3.05 |
| Payables turnover | 7.32 | 8.79 | 9.86 | 9.54 | 9.29 | 10.61 | 11.69 | 10.24 | 7.80 | 6.48 |
| Inventory turnover | 3.09 | 2.97 | 2.75 | 2.79 | 2.70 | 3.13 | 3.04 | 2.55 | 1.84 | 1.68 |
| Asset turnover | 0.84 | 0.80 | 0.66 | 0.57 | 0.53 | 0.52 | 0.41 | 0.58 | 0.81 | 0.91 |
| Average receivables | $857.8M | $710.7M | $693.7M | $718.3M | $666.9M | $621.7M | $584.9M | $458.3M | $373.1M | $334.3M |
| Average payables | $257.3M | $201.7M | $155.2M | $149.0M | $142.6M | $128.6M | $108.9M | $92.4M | $65.0M | $65.0M |
| Average inventory | $609.4M | $596.9M | $556.1M | $510.1M | $490.0M | $435.9M | $419.1M | $370.6M | $275.1M | $250.6M |
| Intangibles / total assets | 31.5% | 38.0% | 42.9% | 44.6% | 44.7% | 45.6% | 49.2% | 47.8% | 5.3% | 6.1% |
Computed from AMRX's annual financial statements (latest annual report filed February 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AMRX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Amneal Pharmaceuticals traded at 56.8 times earnings, against a 10-year median of 12.1. Based on the latest twelve months, the trailing P/E is 39.1 and the forward P/E is 6.3. Amneal Pharmaceuticals earned a return on invested capital of 16.5% in fiscal 2025. It ended the year with $2.7 billion of debt and $310.9 million in cash and short-term investments, net debt of $2.4 billion. The share count rose 71.9% from 189.0M to 324.8M over 9 years.
See the AMRX income statement, the AMRX chart for price history, or the AMRX stock overview for the latest quote and news.
AMRX key metrics FAQ
What is Amneal Pharmaceuticals's P/E ratio?
Amneal Pharmaceuticals's trailing P/E ratio is 39.1 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 6.3. At the end of fiscal 2025 it was 56.8, compared with a 10-year median of 12.1.
What is Amneal Pharmaceuticals's EV/EBITDA?
Amneal Pharmaceuticals's enterprise value was 10.8 times EBITDA at the end of fiscal 2025 (enterprise value $6.5 billion, EBITDA $603.9 million); the current EV/EBITDA is 15.1.
What is Amneal Pharmaceuticals's ROIC?
Amneal Pharmaceuticals's return on invested capital was 16.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Amneal Pharmaceuticals have?
Amneal Pharmaceuticals had total debt of $2.7 billion at the end of fiscal 2025 and $2.4 billion of net debt (4.02 times EBITDA).
What is Amneal Pharmaceuticals's free cash flow yield?
Amneal Pharmaceuticals generated $269.9 million of free cash flow in fiscal 2025, a free cash flow yield of 6.6% on its market value at year-end ($4.1 billion).
What is Amneal Pharmaceuticals's current ratio?
Amneal Pharmaceuticals's current ratio was 2.17 at the end of fiscal 2025: current assets were 2.17 times current liabilities.